Universal Heart Failure Definition Shifts Focus to Preclinical Stages and Etiology-Based Classification

{"The consensus document from AHA, ACC, European Society of Cardiology, and World Heart Federation redefines heart failure as a clinical syndrome with current or prior symptoms and signs caused by structural or functional cardiac abnormality, corroborated by elevated natriuretic peptides or objective evidence of congestion. It introduces four stages from at-risk (Stage A) through advanced disease (Stage D) and mandates reporting of underlying etiologies such as ischemic, hypertensive, or infiltrative cardiomyopathy. This replaces prior symptom-centric approaches that delayed intervention until overt decompensation.","Observational data from global registries indicate heart failure prevalence exceeds 64 million adults, driven by aging populations and rising cardiometabolic disease. The new classification enables standardized trial endpoints and targeted therapies beyond generic neurohormonal blockade, addressing heterogeneity previously masked by the 2021 universal definition. Earlier risk identification could alter trajectories in patients with obesity or diabetes, where subclinical myocardial dysfunction precedes symptoms by years.","Compared with the 2021 guidelines, this update prioritizes biomarker integration and imaging for Stage B preclinical heart failure, potentially expanding eligibility for SGLT2 inhibitors and mineralocorticoid antagonists. Gaps remain in validation across low-resource settings and pediatric populations, where natriuretic peptide thresholds differ. Upcoming 2027 AHA/ACC guidelines must specify implementation metrics to translate classification into reduced hospitalizations.","Evidence calibration: This is a consensus statement synthesizing expert opinion and limited observational cohorts rather than new RCTs. It cannot demonstrate improved outcomes until prospective registries test the framework; next studies require randomized implementation trials measuring diagnostic lead time and mortality in diverse health systems."}